Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Several other analysts also recently commented on CLLS. JMP Securities reiterated a market outperform rating and issued a $6.00 price target on shares of Cellectis in a research report on Friday, May 31st. Oppenheimer dropped their price target on Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a research report on Wednesday, June 12th.

Cellectis Trading Up 8.0 %

Shares of Cellectis stock opened at $2.30 on Friday. Cellectis has a 12-month low of $0.96 and a 12-month high of $3.77. The stock has a market cap of $127.84 million, a price-to-earnings ratio of -1.78 and a beta of 3.10. The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.69. The company has a fifty day simple moving average of $2.07 and a 200-day simple moving average of $2.50.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) EPS for the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. The firm had revenue of $6.50 million for the quarter. On average, equities analysts forecast that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Trading of Cellectis

Several hedge funds have recently made changes to their positions in CLLS. Long Focus Capital Management LLC lifted its position in Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the period. XTX Topco Ltd acquired a new position in Cellectis during the 2nd quarter worth approximately $29,000. Principal Financial Group Inc. lifted its holdings in shares of Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the period. Finally, Baillie Gifford & Co. boosted its stake in shares of Cellectis by 1.3% in the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after buying an additional 10,605 shares in the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.